Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PDL BioPharma Changes Portfolio Strategy | Contract Pharma

What are you searching for?

Sign in
Breaking News

PDL BioPharma Changes Portfolio Strategy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PDL BioPharma, Inc., following a business and portfolio review, has changed its strategic focus to the discovery and development of novel antibodies in oncology and select immunological diseases. According to a company statement, it will realign its organization this fall to support its new strategy.

As a result of this new strategic focus, which does not include cardiovascular disease, PDL plans to sell its commercial assets, including its Cardene, Retavase and IV Busulfex products, as well as the ularitide development-stage cardiovascular product. Also, following a recent Data Monitoring Committee evaluation of data from the ongoing RESTORE 1 trial, the company has decided to terminate the Nuvion (visilizumab) phase III program in ulcerative colitis due to insufficient efficacy and an inferior safety profile.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters